ArticleJournal of translational medicine2025
Positive feedback loop of IGF2BP3/IL6ST/STAT3 facilitates malignant progression in colorectal cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundColorectal adenocarcinoma (COAD) accounts for approximately 90% of colorectal cancer (CRC) cases and is the most common histological subtype of CRC. COAD, a malignancy associated with high morbidity and mortality, remains a topic of debate, with its underlying molecular mechanisms requiring further investigation.
methodsDifferential analysis and survival analysis were used to evaluate IGF2BP3 expression and prognosis. CCK8, colony formation, and the impact of IGF2BP3 on tumor malignancy were analyzed in transwell apples. GEO data were used to screen potential substrates modified by IGF2BP3. Western blotting, RT-qPCR, and RIP-qPCR were used to validate the predictions. Animal models were constructed to validate the tumor-promoting effects of IGF2BP3.
resultsIGF2BP3 is highly expressed in COAD and correlates with poor patient prognosis. IGF2BP3 activates the JAK2/STAT3 signaling pathway by recognizing m6A-modified IL6ST mRNA. STAT3 transcriptionally regulates IGF2BP3. Importantly, IGF2BP3 enhances the malignant phenotype of COAD both in vivo and in vitro.
conclusionsIn this study, we found IGF2BP3 promotes tumor progression in an m6a manner. Mechanistically, IGF2BP3 recognizes and stabilizes IL6ST, activating the JAK2/STAT3 pathway. In turn, STAT3 transcriptionally activates IGF2BP3, forming an IGF2BP3-STAT3 positive feedback loop that promotes tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.